Reuters logo
BRIEF-Ultragenyx initiates phase 3 study of UX007 in patients with disabling movement disorders
April 27, 2017 / 12:43 PM / in 6 months

BRIEF-Ultragenyx initiates phase 3 study of UX007 in patients with disabling movement disorders

April 27 (Reuters) - Ultragenyx Pharmaceutical Inc:

* Ultragenyx initiates global phase 3 study of UX007 in GLUT1 DS patients with disabling movement disorders Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below